Remission Through Early Monitored Insulin Therapy - Duration Month

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Glargine

Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.

DRUG

Lispro

Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.

DEVICE

Dexcom G6

Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.

Trial Locations (1)

15213

UPMC Falk Diabetes Clinic, Pittsburgh

All Listed Sponsors
lead

Sandra Sobel

OTHER

NCT03670641 - Remission Through Early Monitored Insulin Therapy - Duration Month | Biotech Hunter | Biotech Hunter